These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20544053)

  • 41. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
    Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
    Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New perspectives on the management of diabetic peripheral neuropathic pain.
    Jensen TS; Backonja MM; Hernández Jiménez S; Tesfaye S; Valensi P; Ziegler D
    Diab Vasc Dis Res; 2006 Sep; 3(2):108-19. PubMed ID: 17058631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Approach to a patient with diabetic neuropathy.
    Bhatia R; Yadav R
    Natl Med J India; 2008; 21(5):236-42. PubMed ID: 19320324
    [No Abstract]   [Full Text] [Related]  

  • 44. Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies.
    Wu N; Chen SY; Hallett LA; Boulanger L; Fraser KA; Patel CK; Zhao Y
    Pain Pract; 2011; 11(1):48-56. PubMed ID: 20602718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical inquiry: what medications are best for diabetic neuropathic pain?
    Page N; Deluca J; Crowell K
    J Fam Pract; 2012 Nov; 61(11):691-3. PubMed ID: 23256101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
    Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
    Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuropathic cancer pain: the role of adjuvant analgesics.
    Farrar JT; Portenoy RK
    Oncology (Williston Park); 2001 Nov; 15(11):1435-42, 1445; discussion 1445, 1450-3. PubMed ID: 11758872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Can diabetic polyneuropathy be successfully treated?].
    Ziegler D
    MMW Fortschr Med; 2010 Mar; 152(9):64-8. PubMed ID: 20384102
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.
    Ziegler D; Schneider E; Boess FG; Berggren L; Birklein F
    J Diabetes Complications; 2014; 28(5):698-704. PubMed ID: 24862108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.
    Rolim LC; da Silva EM; Flumignan RL; Abreu MM; Dib SA
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD011265. PubMed ID: 31201734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy.
    Evans JD; Jacobs TF; Evans EW
    Ann Pharmacother; 2008 Nov; 42(11):1686-91. PubMed ID: 18940920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diabetic peripheral neuropathic pain: case studies.
    Belgrade MJ; Cole BE; McCarberg BH; McLean MJ
    Mayo Clin Proc; 2006 Apr; 81(4 Suppl):S26-32. PubMed ID: 16608050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis.
    van Nooten F; Treur M; Pantiri K; Stoker M; Charokopou M
    Clin Ther; 2017 Apr; 39(4):787-803.e18. PubMed ID: 28365034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Newer agents for the treatment of painful diabetic peripheral neuropathy.
    Freeman R
    Curr Diab Rep; 2005 Dec; 5(6):409-16. PubMed ID: 16316590
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Painful diabetic neuropathy: advantage of novel drugs over old drugs?
    Ziegler D
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S414-9. PubMed ID: 19875591
    [No Abstract]   [Full Text] [Related]  

  • 56. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
    Bellows BK; Dahal A; Jiao T; Biskupiak J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Socioeconomic deprivation independently predicts symptomatic painful diabetic neuropathy in type 1 diabetes.
    Anderson SG; Malipatil NS; Roberts H; Dunn G; Heald AH
    Prim Care Diabetes; 2014 Apr; 8(1):65-9. PubMed ID: 24211151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Burden of illness in painful diabetic peripheral neuropathy.
    Giannopoulos S; Pelidou SH; Kyritsis AP; Kosmidou M
    J Pain; 2007 Jun; 8(6):530. PubMed ID: 17481958
    [No Abstract]   [Full Text] [Related]  

  • 59. Duloxetine in the management of diabetic peripheral neuropathic pain.
    Ormseth MJ; Scholz BA; Boomershine CS
    Patient Prefer Adherence; 2011; 5():343-56. PubMed ID: 21845034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
    Irving G; Tanenberg RJ; Raskin J; Risser RC; Malcolm S
    Int J Clin Pract; 2014 Sep; 68(9):1130-40. PubMed ID: 24837444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.